Effect of Fermented Protaetia Brevitarsis Seulensis Powder on Alcohol-induced Liver Disease
Launched by PUSAN NATIONAL UNIVERSITY YANGSAN HOSPITAL · Mar 21, 2020
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a special powder made from fermented Protaetia brevitarsis seulensis on people who have liver problems caused by alcohol, known as Alcoholic Liver Disease. The researchers want to see if this powder can help improve liver health over an 8-week period. The trial is currently looking for participants, and anyone aged 39 years or older may qualify if they have certain liver enzyme levels that are higher than normal, indicating liver stress.
To be eligible, participants must not have serious liver or kidney issues, diabetes, a history of viral hepatitis or cancer, uncontrolled high blood pressure, or certain heart conditions. They also shouldn’t have had surgery on their stomach or taken certain medications recently. If someone joins the study, they will receive either the Protaetia powder or a placebo (a harmless substance that looks identical but has no active ingredients) without knowing which one they are getting. This helps ensure the results are reliable. Overall, the trial aims to provide valuable information on a potential new treatment for those struggling with liver disease due to alcohol use.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Gamma-glutamyl transferase ranging from upper limit of reference to four times of upper limit
- Exclusion Criteria:
- • Abnormal liver or renal function (i.e., serum aminotransferase activity \> 3 times of upper limit of reference range and serum creatinine concentrations \> 1.2 mg/dL)
- • Diabetes (diagnosed clinically or fasting glucose level \> 126 mg/dL)
- • History of viral hepatitis or cancer
- • Uncontrolled hypertension
- • History of serious cardiac disease such as angina or myocardial infarction
- • History of gastrectomy
- • History of medication for psychiatric disease
- • Administration of oriental medicine including herbs within the past 4 weeks
About Pusan National University Yangsan Hospital
Pusan National University Yangsan Hospital is a leading medical institution dedicated to advancing healthcare through innovative clinical research and patient-centered care. As a sponsor of clinical trials, the hospital leverages its expertise in various medical disciplines to investigate new therapies, improve treatment protocols, and enhance patient outcomes. With a commitment to ethical standards and rigorous scientific methodology, Pusan National University Yangsan Hospital collaborates with multidisciplinary teams to ensure the highest quality of clinical research, contributing significantly to the global medical community and fostering advancements in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pusan, Ami Dong, Korea, Republic Of
Patients applied
Trial Officials
Sang Yeoup Lee, Professor
Principal Investigator
Pusan National University Yangsan Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials